Merck & Company (MRK) : Zacks Investment Research ranks Merck & Company (MRK) as 3, which is a Hold recommendation. 5 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 7 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 12 research analysts is 2.17, which indicates as a Buy.
Merck & Company (MRK) : 12 investment research analysts covering Merck & Company (MRK) have an average price target of $62.83 for the near short term. The highest target price given by the Brokerage Firm to the stock is $80 and the lowest target is $53 for the short term. Analysts expect the variance to be within $8.1 of the average price.
Merck & Company (NYSE:MRK): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $58.27 and $58.07 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $59.27. The buying momentum continued till the end and the stock did not give up its gains. It closed at $59.16, notching a gain of 2.00% for the day. The total traded volume was 14,327,651 . The stock had closed at $58.00 on the previous day.
Also, In a research note released to the investors, Jefferies maintains its rating on Merck & Company (NYSE:MRK).The analysts at the brokerage house have a current rating of Hold on the shares. In a recent information released to the investors, Jefferies lowers the new price target from $54 per share to $53 per share. The rating by the firm was issued on June 14, 2016. The company shares have rallied 1.13% from its 1 Year high price. On Aug 19, 2015, the shares registered one year high at $61.70 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $56.38 and the 200 Day Moving Average price is recorded at $53.62.
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.